BioNTech , Pfizer propose EU pays half for each cancelled COVID dose: Report

Published On 2023-05-01 08:45 GMT   |   Update On 2023-05-01 08:45 GMT

Bengaluru: Pfizer Inc and BioNTech's new proposal to the European Union, amid a glut of COVID-19 shots, includes a provision for member states to pay half price, or about 10 euros ($11), for each of about 70 million cancelled doses, the Financial Times reported on Sunday.The revised contract would allow the EU to upgrade to newer vaccines tailored to any future COVID-19 variants, the...

Login or Register to read the full article

Bengaluru: Pfizer Inc and BioNTech's new proposal to the European Union, amid a glut of COVID-19 shots, includes a provision for member states to pay half price, or about 10 euros ($11), for each of about 70 million cancelled doses, the Financial Times reported on Sunday.

The revised contract would allow the EU to upgrade to newer vaccines tailored to any future COVID-19 variants, the report added, citing people close to negotiations.
In January, Reuters reported talks between the EU and the two drugmakers aimed at reducing up to 500 million COVID-19 vaccine doses Brussels has committed to buy this year in return for a higher price.
The move comes as the bloc plans to revamp laws governing the $148 billion pharmaceuticals industry in the hope of reviving investment and boosting access to affordable drugs at a time when health budgets are drained by the costs of treating COVID-19.
Pfizer declined to comment on the FT report but said discussions had been conducted 'in good faith by all parties' while partner BioNTech and the European Medicines Agency (EMA) did not respond to Reuters' requests for comments.










Tags:    
Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News